🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. Tobramycin Injection

    United Therapeutics Europe Ltd

    Wound Infection

    phase 3 small molecule active

    1 trial

  2. Tocilizumab 162 mg

    Hoffmann-La Roche

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  3. Topical Beremagene Geperpavec

    Krystal Biotech Netherlands B.V.

    Dystrophic Epidermolysis Bullosa

    phase 3 mab completed

    2 trials

  4. Topical roflumilast

    Arcutis Biotherapeutics

    Chronic Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  5. Topiramate + Cognitive Behavioral Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 3 small molecule active

    1 trial

  6. Topotecan HEXAL 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Anastrozol STADA® 1 mg Filmtabletten, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, VS-6766, LETRO-cell® 2,5 mg Filmtabletten, VS-6063, Letrozol - 1 A Pharma® 2,5 mg Filmtabletten, ZOLSKETIL pegylated liposomal 2 mg/mL concentrate for dispersion for inf

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 3 small molecule active

    1 trial

  7. Tora-Dol 30 mg/ml soluzione iniettabile, Acido Acetilsalicilico Teva Italia 100 mg compresse gastroresistenti, SODIO CLORURO 0,9% BAXTER Soluzione per infusione

    Fondazione Telethon ETS

    Patients scheduled for major surgery for oncologic indication

    phase 3 small molecule active

    1 trial

  8. Tovorafenib, VINCRISIN 1 mg/ml solution injectable, 2 mg, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tovorafenib, VELBE 10 mg Trockensubstanz zur Injektionsbereitung, Vinblastin STADA 10 mg Pulver zur Herstellung einer Injektionslösung, cellcristin® 1 mg/ml Injektionslösung Wirkstoff: Vincristinsulfat, Vincristinesulfaat Teva 1 mg/ml, oplossing voor injectie, Vinblastinesulfaat 1 mg/ml PCH, oplossing voor injectie

    Lacuna Pharma Pty Ltd

    Pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy

    phase 3 small molecule active

    1 trial

  9. Trabectedin EVER Pharma 1 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Pazopanib PharOS 200 mg film-coated tablets, HALAVEN 0.44 mg/ml solution for injection

    INTENSITY THERAPEUTICS, INC.

    liposarcoma (dedifferentiated, myxoid, round cell or pleomorphic), Leiomyosarcoma (non-uterine), Undifferentiated pleomorphic sarcoma

    phase 3 small molecule active

    1 trial

  10. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Atopic Dermatitis

    phase 3 small molecule completed

    3 trials

  11. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Idiopathic Gastroparesis

    phase 3 small molecule active

    2 trials

  12. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Coronavirus Infection

    phase 3 small molecule active

    1 trial

  13. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Nausea and Vomiting

    phase 3 small molecule active

    1 trial

  14. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Motion Sickness

    phase 3 small molecule active

    4 trials

  15. Tramadol

    AVENUE THERAPEUTICS, INC.

    Pain Management

    phase 3 small molecule active

    3 trials

  16. Tranexamic Acid

    United Therapeutics Europe Ltd

    Spinal Injuries

    phase 3 small molecule active

    1 trial

  17. Tranexamic Acid

    Arrowhead Pharmaceuticals Ireland Limited

    Hemorrhagic Shock

    phase 3 small molecule completed

    1 trial

  18. Tranexamic acid

    The First People's Hospital of Lianyungang

    Hemorrhage, Postpartum

    phase 3 small molecule completed

    1 trial

  19. Trastuzumab

    Mylan IRE Healthcare Limited

    Breast Cancer

    phase 3 mab completed

    1 trial

  20. Trastuzumab

    Hoffmann-La Roche

    Metastatic Breast Cancer

    phase 3 small molecule terminated

    1 trial

  21. Trastuzumab

    Celltrion Healthcare Australia Pty Ltd

    HER2-positive Carcinoma of Breast

    phase 3 small molecule completed

    1 trial

  22. Trastuzumab Emtansine

    Hoffmann-La Roche

    Metastatic Breast Cancer

    phase 3 small molecule terminated

    1 trial

  23. Trastuzumab deruxtecan

    AstraZeneca

    Breast Cancer; HER2-positive; Metastatic

    phase 3 small molecule active

    1 trial

  24. Trastuzumab emtansine

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    3 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources